NextGen device with a proven track record for efficacy in treating snoring and sleep apnea. AIO Breathe is the only device that can show enlargement of the entire airway on Cone Beam CT scans, successful treatment of OSA on sleep testing and preserve and protect the TMJ joint. We are poised to disrupt the sleep, cardiovascular, and athletics markets. We seek Series A funding to scale operations, expand into new markets, and drive the development of next-generation health solutions. Why Invest in AIOMEGA? Proven Market Traction: AIO BREATHE™ is 510(k) cleared and has demonstrated strong initial adoption. Current patients report 100% effectiveness in treating obstructive sleep apnea. High-Growth Sectors: We are Positioned in multi-billion-dollar markets with an accelerating demand for AI-integrated, noninvasive health solutions. We don’t adapt treatments based on AI; we build new treatments with AI as the foundation. Innovative Pipeline: AI-driven wearables, oral devices, cardiac catheters, nanotech drug delivery, IoT-AI-robotic integration (AI-RI) harnessing Predictive-AI (P-AI) Algo’s to deliver precise outcomes. First-Mover Advantage in Sports: Our technology shows promise in reducing concussions, improving athlete safety in contact sports, and improving cardiovascular response to training. Join the AIOMEGA Revolution AIOMEGA is at the forefront of a healthcare revolution—bridging medicine, AI, and cutting-edge technology to improve lives. By investing in AIOMEGA, you become part of an elite movement reshaping the future of health, wellness, and performance focused on precise prediction of outcomes and safety.